High Court Again Extends Response Deadline In Review Of 9th Circuit FCA Reversal
WASHINGTON, D.C. — The U.S. Supreme Court on June 21 granted a district court qui tam plaintiff’s second request for additional time to respond to pharmaceutical companies’ petition that seeks review...To view the full article, register now.
Already a subscriber? Click here to view full article